| Business and Basis of Presentation | Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc., or the Company, is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The Company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The Company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The Company maintains an active research effort and has several pipeline programs. The Company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. In January 2018, the Company entered into a collaboration (the "Collaboration") with GlaxoSmithKline ("GSK"). The Collaboration set up a framework for the joint development of the next generation of Quell and the assignment of areas of marketing responsibility. The initial term of the Collaboration runs through 2020. Through June 30, 2018 , GSK paid the Company $8.8 million upon entering the Collaboration and attainment of performance milestones, committed to future performance milestone payments totaling up to $17.7 million , and agreed to co-fund Quell development costs starting in 2019. The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. In recent years, the Company has suffered recurring losses from operations and negative cash flows from operating activities. At June 30, 2018 , the Company had an accumulated deficit of $189.3 million . The Company held cash and cash equivalents of $7.1 million as of June 30, 2018 . The Company believes that these resources, together with the cash to be generated from expected product sales and the potential achievement of additional development milestones under the Collaboration with GSK, will be sufficient to meet its projected operating requirements into 2019 . The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues; (b) delays in achieving Quell development milestones and related payments from GSK; (c) changes the Company may make to the business that affect ongoing operating expenses; (d) changes the Company may make in its business strategy; (e) regulatory developments or inquiries affecting the Company’s existing products and products under development; (f) changes the Company may make in its research and development spending plans; and (g) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company may need to raise additional funds to support its operating and capital needs in 2019 and beyond. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one year period from the date of issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company intends to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected. Certain prior period amounts have been adjusted to reflect the Company's 1-for-8 reverse stock split effected May 11, 2017. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of June 30, 2018 , unaudited statements of operations for the quarters and six months ended June 30, 2018 and 2017 and the unaudited statements of cash flows for the six months ended June 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2017 has been derived from audited financial statements prepared at that date, but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the quarter and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on February 8, 2018 (File No. 001-33351), or the Company’s 2017 Form 10-K. Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Product returns are estimated based on historical data and evaluation of current information. Accounting Standards Update (“ASU”) No. 2014-9, Revenue from Contracts with Customers (“ASU 2014-9”), is a comprehensive revenue recognition standard that superseded nearly all existing revenue recognition guidance. The Company adopted this standard effective January 1, 2018, using the modified retrospective method. Upon adoption, the Company discontinued revenue deferral under the sell-through model and commenced recording revenue upon delivery to distributors, net of estimated returns. Generally, the new standard results in earlier recognition of revenues. Adoption of ASU 2014-09 impacted the previously reported results for the quarter ended June 30, 2017 as follows: As reported After adoption Quarter Ended June 30, 2017 ASU 2014-09 Impact Quarter Ended June 30, 2017 Revenues $ 4,310,059 $ 503,484 $ 4,813,543 Cost of revenues $ 2,639,402 $ 371,714 $ 3,011,116 Gross profit $ 1,670,657 $ 131,770 $ 1,802,427 Net loss applicable to common stockholders $ (3,237,796 ) $ 131,770 $ (3,106,026 ) Net loss per common share applicable to common stockholders, basic and diluted $ (2.49 ) $ 0.10 $ (2.39 ) Adoption of ASU 2014-09 impacted the previously reported results for the six months ended June 30, 2017 as follows: As reported After adoption Six Months Ended June 30, 2017 ASU 2014-09 Impact Six Months Ended June 30, 2017 Revenues $ 8,616,181 $ 511,138 $ 9,127,319 Cost of revenues $ 5,337,004 $ 397,743 $ 5,734,747 Gross profit $ 3,279,177 $ 113,395 $ 3,392,572 Net loss applicable to common stockholders $ (10,511,878 ) $ 113,395 $ (10,398,483 ) Net loss per common share applicable to common stockholders, basic and diluted $ (9.12 ) $ 0.10 $ (9.02 ) Adoption of ASU 2014-09 impacted the previously reported balance sheet as of December 31, 2017 as follows: As reported After adoption December 31, 2017 ASU 2014-09 December 31, 2017 Accounts receivable, net $ 1,049,329 $ 1,353,499 $ 2,402,828 Prepaid expenses and other current assets $ 1,867,803 $ (583,491 ) $ 1,284,312 Total current assets $ 9,103,374 $ 770,008 $ 9,873,382 Accrued product returns $ 666,375 $ 1,292,181 $ 1,958,556 Deferred revenue $ 820,031 $ (820,031 ) $ — Total current liabilities $ 4,581,835 $ 472,150 $ 5,053,985 Accumulated deficit $ (191,338,054 ) $ 297,858 $ (191,040,196 ) Total stockholders’ equity $ 5,017,389 $ 297,858 $ 5,315,247 Accounts receivable are recorded net of the allowance for doubtful accounts which represents the Company’s best estimate of credit losses. Allowance for doubtful accounts was $25,000 as of June 30, 2018 and December 31, 2017 . Two customers accounted for 24% and 29% of total revenue for the quarter and six months ended June 30, 2018 , respectively. One customer accounted for 16% of total revenue for the quarter and six months ended June 30, 2017 . Customers that individually account for greater than 10% of accounts receivables totaled 64% and 66% of accounts receivables as of June 30, 2018 and December 31, 2017 , respectively. Collaboration In January 2018, the Company entered into the Collaboration with GSK. The Company sold to GSK the rights to the Company’s Quell technology for markets outside of the United States, including certain patents and related assets, and agreed to complete development milestones for the next-generation Quell technology. The Company retained exclusive ownership of Quell technology in the U.S. market. GSK agreed to payments totaling up to $26.5 million , of which $5.0 million was paid at closing, $3.8 million was paid upon attainment of the first development milestone, and the balance will be due upon achievement of defined development and commercialization milestones. In addition, the parties agreed to jointly fund future Quell technology development during an initial period starting in 2019. The Company recognized Collaboration income net of costs, within Other income in the Statement of Operations of $3,749,999 and $8,505,704 , for the quarter and six months ended June 30, 2018 , respectively. Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at June 30, 2018 was $298,650 . The total compensation costs are expected to be recognized over a weighted-average period of 2.3 years. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). ASU 2016-2 requires that lessees recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. The provisions of this guidance are effective for annual periods beginning after December 31, 2018, and for interim periods therein. The Company is in the process of evaluating the new standard and assessing the impact, ASU 2016-2 will have on the Company’s financial statements and which adoption method will be used. |
